Nurix Therapeutics NRIX

$ 22.0 -1.68%

Quarterly report 2024-Q3
added 10-11-2024

Nurix Therapeutics Balance Sheet 2011-2024 | NRIX

Annual Balance Sheet Nurix Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-24 M	-52.5 M	-67.5 M	-119 M	-34.8 M	-25.6 M	-	-	-	-	-	-	-
Long Term Debt	23.1 M	6.43 M	9.19 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	7.49 M	5.53 M	3.85 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	61.5 M	85.6 M	49.4 M	-	-	-	-	-	-	-
Total Current Liabilities	87 M	70.7 M	66.3 M	44.5 M	-	-	-	-	-	-	-	-	-
Total Liabilities	155 M	113 M	134 M	106 M	102 M	82.2 M	-	-	-	-	-	-	-
Deferred Revenue	48.1 M	37.6 M	41.2 M	32.8 M	9.61 M	28.4 M	-	-	-	-	-	-	-
Retained Earnings	-545 M	-401 M	-221 M	-104 M	-60.5 M	-38.8 M	-	-	-	-	-	-	-
Total Assets	356 M	417 M	477 M	396 M	44 M	45.4 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	54.6 M	64.5 M	80.5 M	119 M	35 M	-	-	-	-	-	-	-	-
Book Value	200 M	304 M	342 M	290 M	-57.7 M	-36.8 M	-	-	-	-	-	-	-
Total Shareholders Equity	200 M	304 M	342 M	290 M	-57.7 M	-36.8 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Nurix Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	20.6 M	20.9 M	21.8 M	23.1 M	2.64 M	3.76 M	5.11 M	6.43 M	7.74 M	9.04 M	10.3 M	9.19 M	-	-	9.19 M	10.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	137 M	140 M	144 M	155 M	74.4 M	90.7 M	96.1 M	113 M	117 M	128 M	132 M	134 M	118 M	120 M	134 M	106 M	106 M	106 M	106 M	53.6 M	53.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	48 M	46.8 M	46.1 M	48.1 M	32 M	44.1 M	38.3 M	37.6 M	36.3 M	41.3 M	43.2 M	41.2 M	35.2 M	33.8 M	41.2 M	32.8 M	32.8 M	32.8 M	32.8 M	9.61 M	9.61 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-680 M	-631 M	-587 M	-545 M	-503 M	-466 M	-442 M	-401 M	-355 M	-309 M	-263 M	-221 M	-183 M	-154 M	-221 M	-104 M	-104 M	-104 M	-104 M	-60.5 M	-60.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	514 M	511 M	313 M	356 M	308 M	351 M	370 M	417 M	459 M	394 M	438 M	477 M	493 M	518 M	477 M	396 M	396 M	396 M	396 M	44 M	44 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	99 M	117 M	49.8 M	54.6 M	42.3 M	59 M	33.6 M	64.5 M	47.6 M	41.5 M	78.8 M	80.5 M	147 M	188 M	80.5 M	119 M	119 M	119 M	119 M	34.8 M	34.8 M	-	-	25.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	377 M	371 M	169 M	200 M	234 M	260 M	274 M	304 M	343 M	267 M	306 M	342 M	375 M	398 M	342 M	290 M	290 M	290 M	290 M	-9.52 M	-9.52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	377 M	371 M	169 M	200 M	234 M	260 M	274 M	304 M	343 M	267 M	306 M	342 M	375 M	398 M	270 M	290 M	290 M	290 M	290 M	-57.7 M	-57.7 M	-42.2 M	-39.4 M	-36.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency